BioSpace News Archive

New England Biolabs (NEB®), a world leader in the production of reagents for the life science industry, extended its global subsidiary network with the opening of New England Biolabs Australia Pty Ltd.

Focusing on what’s best for the patient, leveraging technology to perform real-time benefit checks, and developing trust and transparency among stakeholders are some of the suggestions to emerge from AMCP’s recent Partnership Forum on “Optimizing Prior Authorization for Appropriate Medication Selection.”

Harvest One Cannabis Inc. (TSXV: HVT, OTCQX: HRVOF – “Harvest One”) and Delivra Corp. (TSXV: DVA – “Delivra”) are pleased to announce today that they have completed the previously announced plan of arrangement (the “Arrangement”) under the provisions of the Business Corporations Act (Ontario), pursuant to which Harvest One acquired all of the issued and outstanding common shares of Delivra

LabShares Newton, a shared office and laboratory incubator for emerging biotechnology and life science companies, announced at Thursday’s MALSI Day that L Stem Therapeutics is the winner of the second Launch@LabShares competition, providing a $50K year-long membership, including scientific and operational support, to this novel diagnostics startup

Today the American Association of Diabetes Educators (AADE) released comprehensive guidance on the care of children and young adults with diabetes across life stages

Today, Healthy.io — the global leader in turning the smartphone camera into a clinical-grade medical device — announced two additions to its leadership team: Daniel Kraft, M.D. has joined the company’s board of directors, and Stephen Clark will head the company’s U.S. operations.

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, presented updated interim results from the biliary cancer cohort of SUMMIT, an ongoing Phase II basket trial examining the efficacy of neratinib in HER2-mutated cancers, at the European Society for Medical Oncology (ESMO) 21st World Congress on Gastrointestinal Cancer 2019, currently taking place in Barcelona, Spain

VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/PME eligible), Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, today announced positive results (topline data) for the Phase IIA study1 of VALEDIA® (active substance: TOTUM-63), which evaluated this product’s efficacy in a prediabetic population, compared to placebo.

Today, the U.S. Food and Drug Administration granted accelerated approval to Xpovio (selinexor) tablets in combination with the corticosteroid dexamethasone for the treatment of adult patients

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the European Commission has approved ULTOMIRIS® (ravulizumab)